Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cocrystal Pharma ( (COCP) ) has provided an announcement.
On February 19, 2026, Cocrystal Pharma announced that its first oral norovirus protease inhibitor, CDI-988, will be featured at the International Conference on Antiviral Research 2026 in Prague, where the company will present Phase 1 data and updates from an ongoing Phase 1b norovirus challenge study at Emory University School of Medicine. CDI-988, designed on Cocrystal’s structure-based platform as a pan-viral 3CL protease inhibitor with broad-spectrum activity against noroviruses and coronaviruses, targets a disease area with no approved antivirals or vaccines, underscoring both the immediate market need and the potential strategic significance of this candidate for Cocrystal’s antiviral franchise.
Norovirus, a highly contagious cause of acute gastroenteritis that spreads rapidly in crowded settings and imposes an estimated $60 billion global and $10.6 billion U.S. annual economic burden, represents a sizable opportunity if CDI-988 proves successful in clinical development. Being selected to present at ICAR, a premier antiviral research forum, reinforces Cocrystal’s visibility among key scientific and industry stakeholders and could strengthen its positioning in the competitive antiviral space, particularly if the early-stage clinical results support further advancement of its pan-viral protease inhibitor program.
The most recent analyst rating on (COCP) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.
Spark’s Take on COCP Stock
According to Spark, TipRanks’ AI Analyst, COCP is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn, shrinking equity base). Technicals also remain bearish with the stock below major moving averages, while positive corporate milestones (trial initiation steps, NIH funding, and insider financing) provide partial offset but do not fully mitigate the fundamental funding and execution risks.
To see Spark’s full report on COCP stock, click here.
More about Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics that target the viral replication process in influenza, coronaviruses including SARS-CoV-2, noroviruses and hepatitis C. The company uses proprietary structure-based drug discovery technologies to design direct-acting antiviral drug candidates aimed at significant unmet medical needs in infectious diseases.
Based in Bothell, Washington and listed on Nasdaq under the ticker COCP, Cocrystal concentrates on small-molecule antivirals with broad-spectrum potential, including pan-viral protease inhibitors that target 3CL viral proteases. Its pipeline is positioned toward indications such as acute and chronic norovirus gastroenteritis and respiratory viral infections, where existing treatment options and approved antivirals remain limited or nonexistent.
Average Trading Volume: 76,180
Technical Sentiment Signal: Strong Sell
Current Market Cap: $12.82M
See more data about COCP stock on TipRanks’ Stock Analysis page.